Biolife solutions announces 2022 fourth quarter and full year preliminary unaudited revenue and introduces 2023 revenue guidance

Record quarterly revenue of $44.4 million up 19% over q4 2021 with cell processing platform revenue growth of 37% record full year revenue of $161.9 million up 36% over 2021, with organic revenue growth of 38% and cell processing platform revenue growth of 53% initial revenue guidance for 2023 of $188 million to $202 million, reflecting overall growth of 16% to 25% over 2022, and excluding covid related revenue, growth of 26% to 35% over 2022 bothell, wash. , jan. 9, 2023 /prnewswire/ --  biolife solutions, inc. (nasdaq: blfs) ("biolife" or the "company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (cgt) and the broader biopharma markets, today announced 2022 fourth quarter and full year preliminary unaudited revenue and introduced 2023 revenue guidance.
BLFS Ratings Summary
BLFS Quant Ranking